Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting

Guangcai Zhong; Ran Kong; Shi Feng; Cong Wang; Qingbo Hao; Weilin Xie; Xiangxiang Zhou

doi:10.1186/s13045-024-01533-w

Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting

J Hematol Oncol. 2024 Mar 22;17(1):14. doi: 10.1186/s13045-024-01533-w.

Authors

Guangcai Zhong^{1

2}, Ran Kong³, Shi Feng⁴, Cong Wang¹, Qingbo Hao⁴, Weilin Xie⁵, Xiangxiang Zhou^{6

7

8

9}

Affiliations

¹ Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No.324, Jingwu Road, Jinan, 250021, Shandong, China.
² Medical Science and Technology Innovation Center, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, 250117, China.
³ Department of Hematology, Shandong Provincial Hospital, Shandong University, No.324, Jingwu Road, Jinan, 250021, Shandong, China.
⁴ Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
⁵ Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China. [email protected].
⁶ Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No.324, Jingwu Road, Jinan, 250021, Shandong, China. [email protected].
⁷ Medical Science and Technology Innovation Center, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, 250117, China. [email protected].
⁸ Department of Hematology, Shandong Provincial Hospital, Shandong University, No.324, Jingwu Road, Jinan, 250021, Shandong, China. [email protected].
⁹ National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 251006, China. [email protected].

Abstract

Protein degraders, emerging as a novel class of therapeutic agents, have gained widespread attention due to their advantages. They have several advantages over traditional small molecule inhibitors, including high target selectivity and ability to target "undruggable" targets and overcome inhibitor drug resistance. Tremendous research and development efforts and massive investment have resulted in rapid advancement of protein degrader drug discovery in recent years. Here, we overview the latest clinical and preclinical updates on protein degraders presented at the 2023 ASH Annual Meeting.

Keywords: Anti-tumor therapy; Hematologic malignancies; Protein degradation.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Congresses as Topic
Drug Discovery
Hematologic Neoplasms* / drug therapy
Humans
Proteolysis*

Abstract

Publication types

MeSH terms

Grants and funding